Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.53 |
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 7/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1121463 | 0.83 | CA9 (0.57) | ERN1ACLYCA12CA1CA2 | |
| SCHEMBL29135017 | 0.81 | GPR35 (0.41) | ERN1ACLYCA1CA2GPR35 | |
| SCHEMBL5011828 | 0.80 | CYP3A4 (0.40) | ERN1ACLYTDP1 | |
| SCHEMBL4144580 | 0.80 | ERN1 (0.69) | ERN1CA12CA1CA2CA9 | |
| SCHEMBL10386462 | 0.77 | ACLY (0.51) | ERN1ACLYCA12CA1CA2 | |
| SCHEMBL12087025 | 0.77 | KMT2A (0.56) | ERN1ACLYCA12CA1CA2 | |
| SCHEMBL5310099 | 0.76 | S100A4 (0.47) | ERN1MEN1ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL4293562 | 0.75 | GPR35 (0.65) | ERN1CA12CA1CA2CA9 | |
| SCHEMBL29858963 | 0.75 | ACLY (0.37) | ACLYTDP1 | |
| SCHEMBL28543052 | 0.75 | GPR35 (0.65) | ERN1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-20220289673-A1 | WDR5-MYC INHIBITORS | VANDERBILT UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
| CN-101253171-B | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | HOFFMANN LA ROCHE | 2011-06-15 | — | — | CN | disclosed |
| EP-1924579-B1 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-02-09 | — | — | EP | disclosed |
| US-20090163517-A1 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | BINGGELI ALFRED | 2009-06-25 | — | — | US | disclosed |
| CN-101253171-A | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | CN | disclosed |
| EP-1924579-A2 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| US-20070093521-A1 | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | US | disclosed |
| WO-2007025897-A2 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| EP-0395251-A1 | Herbicidal sulfonamides | ICI AUSTRALIA LIMITED (AU) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163517-A1 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | SSTR5, NPY5R, NPY1R | ERN1 3843/4885ACLY 1763/4885CA12 3424/4885 |
| US-20220289673-A1 | WDR5-MYC INHIBITORS | MYC, WDR5, MYCBP | ERN1 1068/4885ACLY 3840/4885CA12 4808/4885 |
| US-20070093521-A1 | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | SSTR5, NPY5R, NPY1R | ERN1 3843/4885ACLY 1763/4885CA12 3424/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | ERN1 1068/4885ACLY 3840/4885CA12 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.